| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 155, Issue 3 1393-1403, Copyright © 1995 by American Association of Immunologists
ARTICLES |
L Zitvogel, H Tahara, PD Robbins, WJ Storkus, MR Clarke, MA Nalesnik and MT Lotze
Department of Surgery, University of Pittsburgh Medical Center, PA 15261, USA.
IL-12 is a heterodimeric cytokine produced by macrophages, mitogen stimulated- or EBV infected-B lymphocytes, keratinocytes, and probably dendritic cells, with important immunoregulatory functions in vitro and in vivo. It directly stimulates activated NK and T cells to produce high levels of IFN-gamma, enhances their cytolytic activity, and promotes maturation of Th1 cells as well as IL-2-activated B cells. We have tested paracrine delivery of IL-12 using autologous or allogeneic fibroblasts engineered to secrete high levels of IL-12 to treat established tumors. Injection of IL-12-engineered fibroblasts at the site of an established (day 8) MCA207 sarcoma could efficiently eliminate or suppress tumor growth in a dose-dependent manner, requiring delivery of > 150 ng/kg/dose of bioactive IL-12. Weekly inoculations for 3 wk could also be used to effectively treat a day 4 sarcoma located intradermally in the opposite flank (80% protection using autologous fibroblasts), resulting in long-term protective antitumor immunity. In less immunogenic tumors (MCA102, MC38), 7-day established lung metastases could be significantly reduced (p = 0.001) following IL-12 delivery by fibroblasts and systemic administration of low doses of IL-2. Histologic findings included a mixed infiltrate of CD4+ and CD8+ T effectors and macrophages in the regressing sarcoma on day 21. In a day 41 MCA207 sarcoma locally injected in situ, similar findings were observed. No lymphoid hyperplasia or tissue necrosis were noted in liver, spleen, or lungs in mice receiving repeated inocula of IL-12-engineered fibroblasts. Tests of liver and renal function monitored during the repetitive weekly treatments were within the normal range. IL-12-engineered fibroblasts thus seem to serve as a safe and efficient means to deliver IL-12 in these three tumor models.
This article has been cited by other articles:
|
|
 |
|
  Y.-S. Lee, J.-H. Kim, K.-J. Choi, I.-K. Choi, H. Kim, S. Cho, B. C. Cho, and C.-O. Yun Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and b7-1 in an immunocompetent murine model. Clin. Cancer Res., October 1, 2006; 12(19): 5859 - 5868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tatsumi, J. Huang, W. E. Gooding, A. Gambotto, P. D. Robbins, N. L. Vujanovic, S. M. Alber, S. C. Watkins, H. Okada, and W. J. Storkus Intratumoral Delivery of Dendritic Cells Engineered to Secrete Both Interleukin (IL)-12 and IL-18 Effectively Treats Local and Distant Disease in Association with Broadly Reactive Tc1-type Immunity Cancer Res., October 1, 2003; 63(19): 6378 - 6386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Mandpe, K. Tsung, and J. A. Norton Cure of an Established Nonimmunogenic Tumor, SCC VII, With a Novel Interleukin 12-Based Immunotherapy Regimen in C3H Mice Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Shi, A. L. Rakhmilevich, C. P. Heise, K. Oshikawa, P. M. Sondel, N.-S. Yang, and D. M. Mahvi Intratumoral Injection of Interleukin-12 Plasmid DNA, Either Naked or in Complex with Cationic Lipid, Results in Similar Tumor Regression in a Murine Model Mol. Cancer Ther., September 1, 2002; 1(11): 949 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Le, N. C. Lee, K. Tsung, and J. A. Norton Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12 J. Immunol., December 15, 2001; 167(12): 6765 - 6772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Putzer, T. Stiewe, F. Rodicker, O. Schildgen, S. Ruhm, O. Dirsch, M. Fiedler, U. Damen, B. Tennant, C. Scherer, et al. Large Nontransplanted Hepatocellular Carcinoma in Woodchucks: Treatment With Adenovirus-Mediated Delivery of Interleukin 12/B7.1 Genes J Natl Cancer Inst, March 21, 2001; 93(6): 472 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wigginton, J.-W. Park, M. E. Gruys, H. A. Young, C. L. Jorcyk, T. C. Back, M. J. Brunda, R. M. Strieter, J. Ward, J. E. Green, et al. Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis J. Immunol., January 15, 2001; 166(2): 1156 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Lechanteur, P Delvenne, F Princen, M Lopez, G Fillet, J Gielen, M-P Merville, and V Bours Combined suicide and cytokine gene therapy for peritoneal carcinomatosis Gut, September 1, 2000; 47(3): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Klein, H. Bueler, and R. C. Mulligan Comparative Analysis of Genetically Modified Dendritic Cells and Tumor Cells as Therapeutic Cancer Vaccines J. Exp. Med., May 15, 2000; 191(10): 1699 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Carr-Brendel, D. Markovic, K. Ferrer, M. Smith, J. Taylor-Papadimitriou, and E. P. Cohen Immunity to Murine Breast Cancer Cells Modified to Express MUC-1, a Human Breast Cancer Antigen, in Transgenic Mice Tolerant to Human MUC-1 Cancer Res., May 1, 2000; 60(9): 2435 - 2443. [Abstract] [Full Text]
|
|
|
|
|
|
M. S. Gee, C. J. Koch, S. M. Evans, W. T. Jenkins, C. H. Pletcher Jr., J. S. Moore, H. K. Koblish, J. Lee, E. M. Lord, G. Trinchieri, et al. Hypoxia-mediated Apoptosis from Angiogenesis Inhibition Underlies Tumor Control by Recombinant Interleukin 12 Cancer Res., October 1, 1999; 59(19): 4882 - 4889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Caminschi, E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. W. S. Robinson, and B. Scott Cytokine Gene Therapy of Mesothelioma . Immune and Antitumor Effects of Transfected Interleukin-12 Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 347 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Nishioka, M. Hirao, P. D. Robbins, M. T. Lotze, and H. Tahara Induction of Systemic and Therapeutic Antitumor Immunity Using Intratumoral Injection of Dendritic Cells Genetically Modified to Express Interleukin 12 Cancer Res., August 1, 1999; 59(16): 4035 - 4041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Peng, M. L. Penichet, and S. L. Morrison A Single-Chain IL-12 IgG3 Antibody Fusion Protein Retains Antibody Specificity and IL-12 Bioactivity and Demonstrates Antitumor Activity J. Immunol., July 1, 1999; 163(1): 250 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jiang, D. M. Magee, and R. A. Cox Construction of a Single-Chain Interleukin-12-Expressing Retroviral Vector and Its Application in Cytokine Gene Therapy against Experimental Coccidioidomycosis Infect. Immun., June 1, 1999; 67(6): 2996 - 3001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Mullins, C. J. Burger, and K. D. Elgert Paclitaxel Enhances Macrophage IL-12 Production in Tumor-Bearing Hosts Through Nitric Oxide J. Immunol., June 1, 1999; 162(11): 6811 - 6818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fayolle, D. Ladant, G. Karimova, A. Ullmann, and C. Leclerc Therapy of Murine Tumors with Recombinant Bordetella pertussis Adenylate Cyclase Carrying a Cytotoxic T Cell Epitope J. Immunol., April 1, 1999; 162(7): 4157 - 4162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cavallo, E. D. Carlo, M. Butera, R. Verrua, M. P. Colombo, P. Musiani, and G. Forni Immune Events Associated with the Cure of Established Tumors and Spontaneous Metastases by Local and Systemic Interleukin 12 Cancer Res., January 1, 1999; 59(2): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Fernandez, J.-P. Levraud, H. Haddada, M. Perricaudet, and P. Kourilsky High Frequency of Specific CD8+ T Cells in the Tumor and Blood Is Associated with Efficient Local IL-12 Gene Therapy of Cancer J. Immunol., January 1, 1999; 162(1): 609 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Fogler, K. Volker, M. Watanabe, J. M. Wigginton, P. Roessler, M. J. Brunda, J. R. Ortaldo, and R. H. Wiltrout Recruitment of Hepatic NK Cells by IL-12 Is Dependent on IFN-{gamma} and VCAM-1 and Is Rapidly Down-Regulated by a Mechanism Involving T Cells and Expression of Fas J. Immunol., December 1, 1998; 161(11): 6014 - 6021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Caminschi, E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. Scott, and B. W. S. Robinson Interleukin-12 Induces an Effective Antitumor Response in Malignant Mesothelioma Am. J. Respir. Cell Mol. Biol., November 1, 1998; 19(5): 738 - 746. [Abstract] [Full Text]
|
|
|
|
|
|
W. M. Siders, P. W. Wright, J. A. Hixon, W. G. Alvord, T. C. Back, R. H. Wiltrout, and R. G. Fenton T Cell- and NK Cell-Independent Inhibition of Hepatic Metastases by Systemic Administration of an IL-12-Expressing Recombinant Adenovirus J. Immunol., June 1, 1998; 160(11): 5465 - 5474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Toda, R. L. Martuza, H. Kojima, and S. D. Rabkin In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity J. Immunol., May 1, 1998; 160(9): 4457 - 4464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Lode, T. Dreier, R. Xiang, N. M. Varki, A. S. Kang, and R. A. Reisfeld Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma PNAS, March 3, 1998; 95(5): 2475 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Goedegebuure and T. J. Eberlein Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors Oncologist, October 1, 1997; 2(5): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Putzer, M. Hitt, W. J. Muller, P. Emtage, J. Gauldie, and F. L. Graham Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression PNAS, September 30, 1997; 94(20): 10889 - 10894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Robertson and J. Ritz Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment Oncologist, February 1, 1996; 1(1): 88 - 97. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
